Technical Analysis for ACHL - Achilles Therapeutics plc

Grade Last Price % Change Price Change
C 1.25 5.04% 0.06
ACHL closed up 5.04 percent on Thursday, March 28, 2024, on 32 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Spinning Top Other 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 5.04%
20 DMA Resistance Bearish 0.81%
1,2,3 Pullback Bullish Bullish Swing Setup 0.81%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.81%
Wide Bands Range Expansion 0.81%
Fell Below 20 DMA Bearish 1.63%
Wide Bands Range Expansion 1.63%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 18 hours ago
Gap Up Closed about 18 hours ago
10 DMA Resistance about 18 hours ago
20 DMA Resistance about 18 hours ago
Gap Up Partially Closed about 18 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Antineoplastic Drugs Melanoma Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Triple Negative Breast Cancer Immuno Oncology Biopharmaceutical

Is ACHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.76
52 Week Low 0.7402
Average Volume 872,708
200-Day Moving Average 0.96
50-Day Moving Average 1.12
20-Day Moving Average 1.24
10-Day Moving Average 1.21
Average True Range 0.12
RSI (14) 53.70
ADX 33.05
+DI 20.83
-DI 13.30
Chandelier Exit (Long, 3 ATRs) 1.41
Chandelier Exit (Short, 3 ATRs) 1.40
Upper Bollinger Bands 1.41
Lower Bollinger Band 1.07
Percent B (%b) 0.54
BandWidth 27.32
MACD Line 0.02
MACD Signal Line 0.03
MACD Histogram -0.008
Fundamentals Value
Market Cap 50.98 Million
Num Shares 40.8 Million
EPS -1.90
Price-to-Earnings (P/E) Ratio -0.66
Price-to-Sales 0.00
Price-to-Book 0.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.40
Resistance 3 (R3) 1.40 1.34 1.38
Resistance 2 (R2) 1.34 1.31 1.35 1.37
Resistance 1 (R1) 1.30 1.28 1.32 1.30 1.36
Pivot Point 1.24 1.24 1.26 1.25 1.24
Support 1 (S1) 1.20 1.21 1.22 1.20 1.14
Support 2 (S2) 1.14 1.18 1.15 1.13
Support 3 (S3) 1.10 1.14 1.13
Support 4 (S4) 1.10